Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer

Patent metadata

Field	Value
Publication number	US-10837015-B2
Application number	US-201816158634-A
Country	US
Kind code	B2
Filing date	Oct 12, 2018
Priority date	May 24, 2012
Publication date	Nov 17, 2020
Grant date	Nov 17, 2020

Abstract

Methods and kits for GPP-targeting, e.g., for the treatment of oncogenic Kras-associated cancers, and methods for determining the efficacy of those methods are provided.

First claim

What is claimed is:

1. A method for treating cancer in a subject comprising a cancer cell comprising an oncogenic Kras mutation, the method comprising administering to the subject a therapeutically effective amount of a composition comprising an inhibitor of the glutamine to pyruvate pathway (GPP) enzyme ME1,
wherein the oncogenic Kras mutation is selected from the group consisting of Kras G12D , Kras G12V , Kras G13D , Kras G12C , Kras Q61R , Kras Q61L , Kras Q61K , and Kras G12R .

2. The method of claim 1 , the method further comprising:
determining the level of one or more markers selected from the group consisting of NADP+, NADPH, GSSG, GSH, pyruvate, and reactive oxygen species (ROS), in a sample obtained from the subject; and
concluding that the treatment was effective if the level of one or more of the markers NADP+, GSSG and ROS is increased, relative to each marker's control level, or if the level of one or more of the markers NADPH, GSH and pyruvate is decreased, relative to each marker's control level; or
concluding that the treatment was not effective if the level of one or more of the markers NADP+, GSSG, and ROS is not increased, relative to each marker's control level, or if the level of one or more of the markers NADPH, GSH and pyruvate is not decreased, relative to each marker's control level.

3. The method of claim 2 , comprising determining the level of two or more of the markers selected from the group consisting of NADP+, NADPH, GSSG, GSH, pyruvate, and ROS.

4. The method of claim 3 , comprising determining the level of three or more of the markers selected from the group consisting of NADP+, NADPH, GSSG, GSH, pyruvate, and ROS.

5. The method of claim 4 , comprising determining the level of four or more of the markers selected from the group consisting of NADP+, NADPH, GSSG, GSH, pyruvate, and ROS.

6. The method of claim 5 , comprising determining the level of five or more of the markers selected from the group consisting of NADP+, NADPH, GSSG, GSH, pyruvate, and ROS.

7. The method of claim 6 , comprising determining the level of NADP+, NADPH, GSSG, GSH, pyruvate, and ROS.

8. The method of claim 2 , wherein each marker's control level is the level of the marker in a sample obtained from the same subject prior to or at the beginning of the treatment or from another subject who is known to comprise an oncogenic Kras mutation and is not undergoing or has not undergone a GPP-targeting treatment.

9. The method of claim 2 , wherein each marker's control level is a predetermined reference level of the marker.

10. The method of claim 2 , wherein the ROS is a member selected from the group consisting of hydrogen peroxide, super oxide, hydroxyl radical, hypochlorous acid, nitric oxide, peroxyl radical, and singlet oxygen.

11. The method of claim 2 , wherein the method further comprises determining the level of at least one additional marker selected from the group consisting of glutamine, glutamate, aspartate, αKG, NAD+, NADH, oxaloacetate, malate, MDH1, and MEI.

12. The method of claim 1 , wherein the method further comprises administering a therapeutically effective amount of a composition comprising an inhibitor that targets an additional enzyme of the GPP or that targets a metabolite associated with an enzyme-catalyzed reaction in the GPP.

13. The method of claim 12 , wherein the additional enzyme is selected from the group consisting of Kras, GLS, GOT2, GOT1 and MDH1.

14. The method of claim 12 , wherein the inhibitor targets a metabolite selected from the group consisting of glutamine, glutamate, aspartate, GSH, NADH, NADPH, oxaloacetate, and malate.

15. The method of claim 1 , wherein the subject is a human subject.

16. The method of claim 13 , wherein the subject is a human subject.

17. The method of claim 15 , wherein the cancer is pancreatic cancer, non-small cell lung cancer, colorectal cancer, or biliary cancer.

18. The method of claim 15 , wherein the cancer is pancreatic cancer.

19. The method of claim 1 , wherein the oncogenic Kras mutation is selected from the group consisting of Kras G12C , Kras Q61R , Kras Q61L , Kras Q61K , and Kras G12R .

20. A method for inhibiting growth of a cancer cell in a subject comprising an oncogenic Kras mutation, the method comprising administering to the subject a therapeutically effective amount of a composition comprising an inhibitor of the glutamine to pyruvate pathway (GPP) enzyme ME1,
wherein the oncogenic Kras mutation is selected from the group consisting Kras G12D , Kras G12V , Kras G13D , Kras G12C , Kras Q61R , Kras Q61L , Kras Q61K , and Kras G12R .

21. The method of claim 20 , wherein the method further comprises administering a therapeutically effective amount of a composition comprising an inhibitor that targets an additional enzyme associated with an enzyme-catalyzed reaction of the glutamine to pyruvate pathway (GPP) or that targets a metabolite associated with an enzyme-catalyzed reaction in the GPP.

22. The method of claim 21 , wherein the additional enzyme is selected from the group consisting of Kras, GLS, GOT2, GOT1 and MDH1.

23. The method of claim 15 , wherein the cancer is pancreatic ductal adenocarcinoma.

24. The method of claim 20 , wherein the subject is a human subject.

25. The method of claim 22 , wherein the subject is a human subject.

26. The method of claim 24 , wherein the cancer cell is a pancreatic cancer cell , a non-small cell lung cancer cell, a colorectal cancer cell, or a biliary cancer cell.

27. The method of claim 24 , wherein the cancer cell is a pancreatic cancer cell.

28. The method of claim 24 , wherein the cancer cell is a pancreatic ductal adenocarcinoma cell.

29. The method of claim 20 , wherein the oncogenic Kras mutation is selected from the group consisting of Kras G12C , Kras Q61R , Kras Q61L , Kras Q61K , and Kras G12R .

Assignees

• Dana Farber Cancer Inst Inc
• Beth Israel Deaconess Medical Ct Inc

Inventors

• Kimmelman Alec C
• Son Jaekyoung
• Cantley Lewis
• Lyssiotis Costas A

Classifications

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• C12Q1/34

  involving hydrolase · CPC title

• C12N2310/16

  Aptamers · CPC title

• G01N2333/914

  Hydrolases (3) · CPC title